• <em>DPYD*7</em> as a Predictor of Severe Fluoropyrimidine-Related Adverse Events
• <em>DPYD</em> Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
• <em>DPYD</em> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
• <em>DPYD</em> genotyping and predicting fluoropyrimidine toxicity: where do we stand?
• <em>DPYD</em> Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment
• 5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity
• 5-Fluorouracil Neurotoxicity in the Absence of Dihydropyrimidine Dehydrogenase Deficiency Case Report
• A Case of Colon Cancer with Suspected DPD Deficiency Causing Severe Adverse Effects following Adjuvant Chemotherapy with Capecitabine
• A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma
• A Facile Method for the Quantification of Urinary Uracil Concentration by a Uracil-Specific Fluorescence Derivatization Reaction
• A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen
• A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report
• A Rare Genetic-Metabolic Cause of Epileptic Spasms: Dihydropyrimidine Dehydrogenase Deficiency
• An Evaluation of the Diagnostic Accuracy of a Panel of Variants in <em>DPYD</em> and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities
• Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation
• Assessing the Hepatotoxic Effects of Fluoropyrimidine Chemotherapy in Male Iraqi Colorectal Cancer Patients
• Autism: Screening of inborn errors of metabolism and unexpected results
• Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia
• Can we identify patients carrying targeted deleterious <em>DPYD</em> variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis
• Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
• Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
• CIAO1 and MMS19 deficiency: A lethal neurodegenerative phenotype caused by cytosolic Fe-S cluster protein assembly disorders
• Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference
• Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study
• Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
• Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer
• Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency
• Design and Implementation of an Opt-Out, End-to-End, Preemptive <em>DPYD</em> Testing Program for Patients Planned for a Systemic Fluoropyrimidine
• Detecting DPD deficiency: when perfect is the enemy of good
• Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments
• Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping
• Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
• Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis
• Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
• Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
• DPD deficiency in an Irish oncology centre: Prevalence and clinical implications
• DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
• Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
• Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with <em>DPYD</em> Genetic Polymorphism: A Systematic Review and Meta-Analysis
• Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
• Ethnic Diversity of DPD Activity and the <em>DPYD</em> Gene: Review of the Literature
• Evaluation of the Tasso-SST® capillary blood microsampling device for the measurement of endogenous uracil levels
• Focal Neurotoxicity Associated With Topical 5-Fluorouracil
• How I treat stage II colon cancer patients
• Identification of <em>DPYD</em> variants and estimation of uracil and dihydrouracil in a healthy Indian population
• Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis
• Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing
• Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events
• Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
• Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
• Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
• Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: <em>DPYD</em> genotyping to guide chemotherapy dosing in Greece
• Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics
• Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population
• Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature
• Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur)
• Lay understandings of drug-gene interactions: The right medication, the right dose, at the right time, but what are the right words?
• Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants
• Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine
• Lymph node metastatic penile cancer: a challenge in uro-oncology-guideline-conform treatment
• Near Miss or Standard of Care? <em>DPYD</em> Screening for Cancer Patients Receiving Fluorouracil
• Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis
• Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey
• Pharmacogenetic Variants Can Influence Optical Medication Use
• Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine
• Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report
• Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
• Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a <em>DPYD</em> variant and decreased dihydropyrimidine dehydrogenase enzyme activity
• Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
• Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma
• Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report
• Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine
• Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of <em>DPYD</em> Exon Sequencing and the Role of Phenotyping Assays
• Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
• Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population
• Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results
• Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy
• Quantitation of Pyrimidine in Urine by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
• Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
• Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency: Rapid Review
• Rapid determination of uracil in biological fluids at mercury thin film electrode for early detection of potential 5-fluorouracil toxicity due to dihydropyrimidine dehydrogenase deficiency
• Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients
• Renal impairment and DPD testing: Watch out for false-positive results!
• Reversible Toxic Encephalopathy Involving the Cerebellum and Subcortical White Matter Attributed to Capecitabine
• Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles
• Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives
• Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?
• Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review
• Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
• Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines
• Short-term biological variation of plasma uracil in a Caucasian healthy population
• Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency
• Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US
• Survey of US Medical Oncologists' Practices and Beliefs Regarding <em>DPYD</em> Testing Before Fluoropyrimidine Chemotherapy
• Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients
• Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
• The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine)
• The Incidence of Hematological Toxicities in Colorectal Cancer Patients Treated With Fluoropyrimidine-Based Regimens at Princess Noorah Oncology Center
• Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom
• Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series